Document 1176
 DOCN  M94A1176
 TI    Immune evolution markers in HIV infection. Effect induced by treatment.
 DT    9412
 AU    Tuset C; Ferrer C; Casas E; Pedro F; Carbonell F; Herrera A;
       Lopez-Santovena F; Immunology Medicine Department, H. General
       Universitario,; C.T.C.V. Valencia, Spain.
 SO    Int Conf AIDS. 1994 Aug 7-12;10(2):191 (abstract no. PB0776). Unique
       Identifier : AIDSLINE ICA10/94371399
 AB    Several immunological parameters were analyzed in 33 healthy controls
       and 120 HIV infected patients who have been followed during 3 years. The
       infected patients can be separated in 73 without any treatment and 47
       with zidovudine (ZDV). At the end of the follow-up 58 were asymptomatic
       and 62 had some symptoms or AIDS. The aim of this work is to evaluate
       the changes which can happen with antiretroviral treatment. By flow
       cytometry (FACScan, Becton-Dickinson) were measured CD3, CD4, CD8, CD25
       (IL-2R), CD3+CD25, B, NK cells and monocytes. Soluble interleukin-2
       receptor (sIL-2R) was analyzed by EIA (Eurogenetics), Beta 2
       microglobulin (B2M) by IMx (Abbott), IgG, IgM, IgA by nephelometry
       (Beckman). Cell counts (CD4, CD25, CD3+CD25) decreased in patients
       without treatment (p < 0.01) during the follow-up. In patients with ZDV
       treatment the CD4 counts were maintained although CD3+CD25 did not
       change the decreasing evolution. B2M and sIL-2R in untreated patients
       showed an increasing evolution (B2M p < 0.01, sIL-2R p < 0.05). B2M
       decreased in asymptomatic treated patients during the first year of
       follow-up (p non significative) but not in the following controls or in
       AIDS patients. The levels of sIL-2R decreased in asymptomatic treated
       patients at the begining of treatment (p < 0.05). IgA levels showed an
       increasing in patients treated and not treated during evolution with
       statistical differences (p < 0.01). To sum up, serum sIL-2R
       determination could be a useful marker for active HIV replication in
       monitoring ZDV therapy and might play a role in future studies dealing
       with antiretroviral drug therapy in early phases of infection.
 DE    beta 2-Microglobulin/ANALYSIS  Antigens, CD/*BLOOD
       B-Lymphocytes/IMMUNOLOGY  Biological Markers/BLOOD  Comparative Study
       Flow Cytometry/METHODS  Follow-Up Studies  Human  HIV/PHYSIOLOGY  HIV
       Infections/BLOOD/*DRUG THERAPY/*IMMUNOLOGY  IgA/BLOOD  IgG/BLOOD
       IgM/BLOOD  Immunoglobulins/*BLOOD  Killer Cells, Natural/IMMUNOLOGY
       Monocytes/IMMUNOLOGY  Receptors, Interleukin-2/*ANALYSIS  Reference
       Values  Time Factors  Virus Replication  Zidovudine/*THERAPEUTIC USE
       MEETING ABSTRACT

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).